Ionis jumps as Q1 revenue nearly doubles and 2026 guidance is raised
Ionis shares rose after the company reported first-quarter 2026 results on April 29, 2026 that showed an 87% year-over-year revenue jump to $246 million. Management raised full-year 2026 total revenue guidance to $875–$900 million (from $800–$825 million) and tightened its expected operating loss outlook.
1. What’s moving the stock
Ionis Pharmaceuticals is higher today after releasing first-quarter 2026 earnings and updating its full-year outlook on April 29, 2026. The company said revenue rose 87% year over year, supported by higher commercial revenue from its launched products and meaningful research-and-development revenue, including milestone payments tied to partner programs. (stocktitan.net)
2. The numbers investors are reacting to
Ionis reported total revenue of $246 million for Q1 2026 versus $132 million a year earlier, with net product sales of $43 million that included $27 million from TRYNGOLZA and $16 million from DAWNZERA. Ionis also flagged about $95 million of milestone payments from multiple partnerships as a key driver of the quarter’s collaboration/R&D revenue. (stocktitan.net)
3. Guidance raise adds fuel
Ionis lifted full-year 2026 total revenue guidance to $875–$900 million from $800–$825 million and said it reduced its expected operating loss range (non-GAAP) as commercial momentum and year-to-date revenue performance improved. The company also highlighted ongoing launch execution and preparations across its commercial portfolio as a major 2026 focus. (stocktitan.net)
4. Near-term items to watch
Investors will likely focus on whether newly launched products can keep scaling while Ionis continues investing ahead of additional potential launches, and whether milestone-heavy collaboration revenue remains a tailwind through the year. Ionis also noted an FDA Priority Review with a PDUFA target action date of June 30, 2026 for an additional olezarsen indication, a key upcoming catalyst on the calendar. (stocktitan.net)